Therapeutic options for mucinous ovarian carcinoma

被引：55

作者：

Gorringe, Kylie L. ^{[1
,2
]}

Cheasley, Dane ^{[1
,2
]}

Wakefield, Matthew J. ^{[2
,3
]}

Ryland, Georgina L. ^{[1
]}

Allan, Prue E. ^{[1
]}

Alsop, Kathryn ^{[1
,2
]}

Amarasinghe, Kaushalya C. ^{[1
]}

Ananda, Sumitra ^{[1
,4
]}

Bowtell, David D. L. ^{[1
,2
]}

Christie, Michael ^{[2
,5
]}

Chiew, Yoke-Eng ^{[6
,7
]}

Churchman, Michael ^{[8
]}

DeFazio, Anna ^{[6
,7
,9
]}

Fereday, Sian ^{[1
,2
]}

Gilks, C. Blake ^{[10
]}

Gourley, Charlie ^{[8
]}

Hadley, Alison M. ^{[11
]}

Hendley, Joy ^{[1
]}

Hunter, Sally M. ^{[1
]}

Kaufmann, Scott H. ^{[12
]}

Kennedy, Catherine J. ^{[6
]}

Kobel, Martin ^{[13
]}

Le Page, Cecile ^{[14
]}

Li, Jason ^{[1
]}

Lupat, Richard ^{[1
]}

McNally, Orla M. ^{[3
,15
]}

McAlpine, Jessica N. ^{[10
]}

Pyman, Jan ^{[15
,16
]}

Rowley, Simone M. ^{[1
]}

Salazar, Carolina ^{[1
]}

Saunders, Hugo ^{[1
]}

Semple, Timothy ^{[1
]}

Stephens, Andrew N. ^{[17
]}

Thio, Niko ^{[1
]}

Torres, Michelle C. ^{[1
]}

Traficante, Nadia ^{[1
,2
]}

Zethoven, Magnus ^{[1
]}

Antill, Yoland C. ^{[18
,19
]}

Campbell, Ian G. ^{[1
,2
]}

Scott, Clare L. ^{[1
,2
,3
,5
,15
]}

机构：

[1] Peter MacCallum Canc Ctr, 305 Grattan SE, Melbourne, Vic, Australia

[2] Univ Melbourne, Melbourne, Vic, Australia

[3] Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia

[4] Western Hlth, St Albans, Australia

[5] Royal Melbourne Hosp, Parkville, Vic, Australia

[6] Westmead Hosp, Dept Gynaecol Oncol, Sydney, NSW, Australia

[7] Westmead Inst Med Res, Sydney, NSW, Australia

[8] Univ Edinburgh, Canc Res UK Edinburgh Ctr, Nicola Murray Ctr Ovarian Canc Res, Edinburgh, Midlothian, Scotland

[9] Univ Sydney, Sydney, NSW, Australia

[10] Univ British Columbia, Vancouver, BC, Canada

[11] Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia

[12] Mayo Clin, Rochester, MN USA

[13] Univ Calgary, Calgary, AB, Canada

[14] CRCHUM, Montreal, PQ, Canada

[15] Royal Womens Hosp, Parkville, Vic, Australia

[16] Royal Childrens Hosp, Flemington, Australia

[17] Hudson Inst Med Res, Clayton, Vic, Australia

[18] Cabrini Hlth, Malvern, Australia

[19] Frankston Hosp, Frankston, Australia

来源：

GYNECOLOGIC ONCOLOGY | 2020年 / 156卷 / 03期

基金：

澳大利亚国家健康与医学研究理事会; 英国医学研究理事会; 美国国家卫生研究院;

关键词：

Ovarian cancer; Precision oncology; Molecular targeted therapy; Therapy; Sequencing; Genomic; CANCER-PATIENTS; CLINICOPATHOLOGICAL FEATURES; ESTROGEN-RECEPTOR; EXPRESSION; INHIBITORS; FREQUENCY; WOMEN; ADENOCARCINOMA; DEFICIENCY; KINASE;

D O I：

10.1016/j.ygyno.2019.12.015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objective. Mutinous ovarian carcinoma (MOC) is an uncommon ovarian cancer histotype that responds poorly to conventional chemotherapy regimens. Although long overall survival outcomes can occur with early detection and optimal surgical resection, recurrent and advanced disease are associated with extremely poor survival. There are no current guidelines specifically for the systemic management of recurrent MOC. We analyzed data from a large cohort of women with MOC to evaluate the potential for clinical utility from a range of systemic agents. Methods. We analyzed gene copy number (n = 191) and DNA sequencing data (n = 184) from primary MOC to evaluate signatures of mismatch repair deficiency and homologous recombination deficiency, and other genetic events. Immunohistochemistry data were collated for ER, CK7, CK20, CDX2, HER2, PAX8 and p16 (n = 117-166). Results. Molecular aberrations noted in MOC that suggest a match with current targeted therapies include amplification of ERBB2 (26.7%) and BRAF mutation (9%). Observed genetic events that suggest potential efficacy for agents currently in clinical trials include: KRAS/NRAS mutations (66%), TP53 missense mutation (49%), RNF43 mutation (11%), ARID1A mutation (10%), and PIK3CA/PIEN mutation (9%). Therapies exploiting homologous recombination deficiency (HRD) may not be effective in MOC, as only 1/191 had a high HRD score. Mismatch repair deficiency was similarly rare (1/184). Conclusions. Although genetically diverse, MOC has several potential therapeutic targets. Importantly, the lack of response to platinum-based therapy observed clinically corresponds to the lack of a genomic signature associated with HRD, and MOC are thus also unlikely to respond to PARP inhibition. (C) 2019 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

引用

页码：552 / 560

页数：9

共 46 条

[1]

Ajani Mustapha Akanji, 2017, Pan Afr Med J, V27, P259, DOI 10.11604/pamj.2017.27.259.11883

[2] Signatures of mutational processes in human cancer [J].

Alexandrov, Ludmil B. ;

Nik-Zainal, Serena ;

Wedge, David C. ;

Aparicio, Samuel A. J. R. ;

Behjati, Sam ;

Biankin, Andrew V. ;

Bignell, Graham R. ;

Bolli, Niccolo ;

Borg, Ake ;

Borresen-Dale, Anne-Lise ;

Boyault, Sandrine ;

Burkhardt, Birgit ;

Butler, Adam P. ;

Caldas, Carlos ;

Davies, Helen R. ;

Desmedt, Christine ;

Eils, Roland ;

Eyfjord, Jorunn Erla ;

Foekens, John A. ;

Greaves, Mel ;

Hosoda, Fumie ;

Hutter, Barbara ;

Ilicic, Tomislav ;

Imbeaud, Sandrine ;

Imielinsk, Marcin ;

Jaeger, Natalie ;

Jones, David T. W. ;

Jones, David ;

Knappskog, Stian ;

Kool, Marcel ;

Lakhani, Sunil R. ;

Lopez-Otin, Carlos ;

Martin, Sancha ;

Munshi, Nikhil C. ;

Nakamura, Hiromi ;

Northcott, Paul A. ;

Pajic, Marina ;

Papaemmanuil, Elli ;

Paradiso, Angelo ;

Pearson, John V. ;

Puente, Xose S. ;

Raine, Keiran ;

Ramakrishna, Manasa ;

Richardson, Andrea L. ;

Richter, Julia ;

Rosenstiel, Philip ;

Schlesner, Matthias ;

Schumacher, Ton N. ;

Span, Paul N. ;

Teague, Jon W. .

NATURE, 2013, 500 (7463) :415-+

[3] BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group [J].

Alsop, Kathryn ;

Fereday, Sian ;

Meldrum, Cliff ;

deFazio, Anna ;

Emmanuel, Catherine ;

George, Joshy ;

Dobrovic, Alexander ;

Birrer, Michael J. ;

Webb, Penelope M. ;

Stewart, Colin ;

Friedlander, Michael ;

Fox, Stephen ;

Bowtell, David ;

Mitchell, Gillian .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) :2654-2663

[4] Inferring copy number and genotype in tumour exome data [J].

Amarasinghe, Kaushalya C. ;

Li, Jason ;

Hunter, Sally M. ;

Ryland, Georgina L. ;

Cowin, Prue A. ;

Campbell, Ian G. ;

Halgamuge, Saman K. .

BMC GENOMICS, 2014, 15

[5] Prognostic evaluation of tumour type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel/carboplatin chemotherapy: Cell type is the most useful prognostic factor [J].

Bamias, A. ;

Sotiropoulou, M. ;

Zagouri, F. ;

Trachana, P. ;

Sakellariou, K. ;

Kostouros, E. ;

Kakoyianni, K. ;

Rodolakis, A. ;

Vlahos, G. ;

Haidopoulos, D. ;

Thomakos, N. ;

Antsaklis, A. ;

Dimopoulos, M. A. .

EUROPEAN JOURNAL OF CANCER, 2012, 48 (10) :1476-1483

[6] The immune system and response to HER2-targeted treatment in breast cancer [J].

Bianchini, Giampaolo ;

Gianni, Luca .

LANCET ONCOLOGY, 2014, 15 (02) :E58-E68

[7] The molecular origin and taxonomy of mucinous ovarian carcinoma [J].

Cheasley, Dane ;

Wakefield, Matthew J. ;

Ryland, Georgina L. ;

Allan, Prue E. ;

Alsop, Kathryn ;

Amarasinghe, Kaushalya C. ;

Ananda, Sumitra ;

Anglesio, Michael S. ;

Au-Yeung, George ;

Bohm, Maret ;

Bowtell, David Dl ;

Brand, Alison ;

Chenevix-Trench, Georgia ;

Christie, Michael ;

Chiew, Yoke-Eng ;

Churchman, Michael ;

DeFazio, Anna ;

Demeo, Renee ;

Dudley, Rhiannon ;

Fairweather, Nicole ;

Fedele, Clare G. ;

Fereday, Sian ;

Fox, Stephen B. ;

Gilks, C. Blake ;

Gourley, Charlie ;

Hacker, Neville F. ;

Hadley, Alison M. ;

Hendley, Joy ;

Ho, Gwo-Yaw ;

Hughes, Siobhan ;

Hunstman, David G. ;

Hunter, Sally M. ;

Jobling, Tom W. ;

Kalli, Kimberly R. ;

Kaufmann, Scott H. ;

Kennedy, Catherine J. ;

Kobel, Martin ;

Le Page, Cecile ;

Li, Jason ;

Lupat, Richard ;

McNally, Orla M. ;

McAlpine, Jessica N. ;

Mes-Masson, Anne-Marie ;

Mileshkin, Linda ;

Provencher, Diane M. ;

Pyman, Jan ;

Rahimi, Kurosh ;

Rowley, Simone M. ;

Salazar, Carolina ;

Samimi, Goli .

NATURE COMMUNICATIONS, 2019, 10 (1)

[8] The Histomorphology of Lynch Syndrome-associated Ovarian Carcinomas Toward a Subtype-specific Screening Strategy [J].

Chui, Michael Herman ;

Ryan, Paul ;

Radigan, Jordan ;

Ferguson, Sarah E. ;

Pollett, Aaron ;

Aronson, Melyssa ;

Semotiuk, Kara ;

Holter, Spring ;

Sy, Keiyan ;

Kwon, Janice S. ;

Soma, Anita ;

Singh, Naveena ;

Gallinger, Steven ;

Shaw, Patricia ;

Arseneau, Jocelyne ;

Foulkes, William D. ;

Gilks, C. Blake ;

Clarke, Blaise A. .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2014, 38 (09) :1173-1181

[9] Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal [J].

Gao, Jianjiong ;

Aksoy, Buelent Arman ;

Dogrusoz, Ugur ;

Dresdner, Gideon ;

Gross, Benjamin ;

Sumer, S. Onur ;

Sun, Yichao ;

Jacobsen, Anders ;

Sinha, Rileen ;

Larsson, Erik ;

Cerami, Ethan ;

Sander, Chris ;

Schultz, Nikolaus .

SCIENCE SIGNALING, 2013, 6 (269) :pl1

[10] Risk Factors for Epithelial Ovarian Cancer by Histologic Subtype [J].

Gates, Margaret A. ;

Rosner, Bernard A. ;

Hecht, Jonathan L. ;

Tworoger, Shelley S. .

AMERICAN JOURNAL OF EPIDEMIOLOGY, 2010, 171 (01) :45-53

← 1 2 3 4 5 →